stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) Return on assets
Sotera Health Company's return on assets over the twelve months to 30 September 2026 was 5.28%, up 2.8 percentage points from fiscal 2025 (2.46%). Over the past ten years it has ranged from −7.91% (fiscal 2022) to 4.21% (fiscal 2021); the current reading is higher than 88% of that period. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 2.46% | 1.03 |
| FY2024 | 1.43% | (0.21) |
| FY2023 | 1.64% | 9.55 |
| FY2022 | −7.91% | (12.12) |
| FY2021 | 4.21% | 5.66 |
| FY2020 | −1.45% | (0.66) |
| FY2019 | −0.79% | (0.36) |
| FY2018 | −0.43% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CDNA CareDx, Inc. compare | 24.0% |
| BLLN BillionToOne, Inc. compare | 9.02% |
| VCYT Veracyte, Inc. compare | 8.63% |
| QGEN QIAGEN N.V. compare | 6.99% |
| SHC Sotera Health Company | 5.28% |
| RDNT RadNet, Inc. compare | −0.55% |
| NEO NeoGenomics, Inc. compare | −2.35% |
| ADPT Adaptive Biotechnologies Corporation compare | −12.0% |
| GRAL GRAIL, Inc. compare | −15.2% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement